Characterization of Site-Specific ScFv PEGylation for Tumor-Targeting Pharmaceuticals
- 31 December 2004
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 16 (1) , 113-121
- https://doi.org/10.1021/bc0498121
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Production of Soluble ScFvs with C-Terminal-Free Thiol for Site-Specific Conjugation or Stable Dimeric ScFvs on DemandBioconjugate Chemistry, 2003
- Diagnostic, surgical and medical aspect of the midgut carcinoidsCancer Treatment Reviews, 2002
- Improving the efficacy of antibody-based cancer therapiesNature Reviews Cancer, 2001
- Design and application of diabodies, triabodies and tetrabodies for cancer targetingJournal of Immunological Methods, 2001
- Peptide and protein PEGylation: a review of problems and solutionsPublished by Elsevier ,2001
- Antibody EngineeringAnnual Review of Biomedical Engineering, 2000
- Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary BypassCirculation, 1999
- Branched and Linear Poly(Ethylene Glycol): Influence of the Polymer Structure on Enzymological, Pharmacokinetic, and Immunological Properties of Protein ConjugatesJournal of Bioactive and Compatible Polymers, 1997
- A Branched Monomethoxypoly(ethylene glycol) for Protein ModificationBioconjugate Chemistry, 1995
- Making Antibodies by Phage Display TechnologyAnnual Review of Immunology, 1994